Register for our free email digests:
Latest From Integra LifeSciences
M&A deals rained down in April with the highest number of acquisitions of the year to date. The month saw 14 M&A deals, up by four from March's total, but still down from the 16 deals recorded in April 2016.
Integra LifeSciences surged to industry-leading 12% sales growth in 2016, and that's before it prepares to consolidate two of the biggest acquisitions in its history. What is the strategy behind the success of the specialty surgery, orthopedics and tissue tech company that is looking at another double-digit sales uplift in 2017?
Despite being a slow month, megadeals abounded in February, as the medtech M&A market saw a hat-trick of billion-dollar deals. Medtech Insight recorded 12 deals for the month, on par with January's volume but down from 16 in February 2016.
Only a month after buying the tissue regeneration company Derma Sciences, Integra has announced a much larger acquisition for Codman Neurosurgery. The company says the buy would complement its current neurosurgery portfolio and boost its global reach.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Medical Devices
- Generic Drugs
- Drug Delivery
- Therapeutic Areas
- Infectious & Viral Diseases
- Neurology, Nervous System
- Respiratory, Pulmonary
- Western Europe
- Parent & Subsidiaries
- Orion Corp.
- Senior Management
Timo Lappalainen , Pres., CEO & Chmn.
Jari Karlson, CFO
Satu Ahomaki, SVP, Global Sales
Reijo Salonen, MD, PhD, SVP, Pharma R&D & CMO
- Contact Info
Phone: (358) 10 4261
Orionintie 1A 02200
P.O. Box 65 Espoo, 02101
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.